Cardiff Oncology, Inc. (CRDF)

NASDAQ: CRDF · IEX Real-Time Price · USD
1.76
-0.03 (-1.68%)
Feb 1, 2023, 9:44 AM EST - Market open
-1.68%
Market Cap 79.97M
Revenue (ttm) 391,000
Net Income (ttm) -39.47M
Shares Out 44.68M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,340
Open 1.78
Previous Close 1.79
Day's Range 1.76 - 1.79
52-Week Range 1.13 - 3.56
Beta 1.60
Analysts Buy
Price Target 8.16 (+363.64%)
Earnings Date Feb 23, 2023

About CRDF

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for met... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 22
Stock Exchange NASDAQ
Ticker Symbol CRDF
Full Company Profile

Financial Performance

In 2021, CRDF's revenue was $359,000, a decrease of -1.91% compared to the previous year's $366,000. Losses were -$28.32 million, 25.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is $8.16, which is an increase of 363.64% from the latest price.

Price Target
$8.16
(363.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference

SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

3 weeks ago - PRNewsWire

Cardiff Oncology to Present at Upcoming Investor Conferences

SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

2 months ago - PRNewsWire

Cardiff Oncology to Present at the Jefferies London Healthcare Conference

SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

3 months ago - PRNewsWire

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 25.93% and 24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates

Data from Phase 1b/2 trial in KRAS-mutated metastatic colorectal cancer (mCRC), per September 12 th announcement, show durable responses to treatment and support initiation of ONSEMBLE, a randomized P...

3 months ago - PRNewsWire

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates

Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib's contribution to SoC and position for a possible accelerated approval opportunity; topline data expe...

5 months ago - PRNewsWire

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022

Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC...

5 months ago - PRNewsWire

Cardiff Oncology to Present at Upcoming Investor Conferences in September

SAN DIEGO , Sept. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

5 months ago - PRNewsWire

Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022

SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

5 months ago - PRNewsWire

Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022

Event to feature discussions on the planned development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer and updates on other development programs Event to take place at 4:30 PM ET...

5 months ago - PRNewsWire

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 4% and 21.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates

Initial preclinical data in ovarian cancer presented at AACR showed treatment with onvansertib plus olaparib leading to a statistically significant survival benefit compared to treatment with either a...

6 months ago - PRNewsWire

Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022

SAN DIEGO , July 5, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

7 months ago - PRNewsWire

Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 17, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, t...

9 months ago - PRNewsWire

Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates

Reported new Phase 1b/2 data from lead KRAS-mutated metastatic colorectal cancer (mCRC) clinical program showing objective response rate and median progression-free survival that substantially exceed ...

9 months ago - PRNewsWire

Cardiff Oncology Announces Departure of Chief Medical Officer

SAN DIEGO , April 12, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers...

10 months ago - PRNewsWire

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

Trial evaluates onvansertib in combination with abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients showing initial abiraterone resistance by rising PSA Dise...

10 months ago - PRNewsWire

Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models

- Combining onvansertib with the PARP inhibitor (PARPi) olaparib led to statistically significant survival benefits compared to treatment with either agent alone in PARPi-resistant ovarian cancer mode...

10 months ago - PRNewsWire

Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC

SAN DIEGO, March 22, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

11 months ago - PRNewsWire

Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting

SAN DIEGO, March 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

11 months ago - PRNewsWire

Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference

SAN DIEGO, March 1, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

1 year ago - PRNewsWire

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -35.29% and 90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

1 year ago - PRNewsWire